Welcome to our dedicated page for Fennec Pharmaceuticals news (Ticker: FENC), a resource for investors and traders seeking the latest updates and insights on Fennec Pharmaceuticals stock.
Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX) is a specialty pharmaceutical company focused on reducing cisplatin-induced ototoxicity in cancer patients through its therapy PEDMARK®. The FENC news feed on Stock Titan aggregates company announcements, clinical updates, capital markets activity and regulatory developments that shape the outlook for this ototoxicity-focused business.
Investors and healthcare observers can review news about regulatory and commercial milestones for PEDMARK® in the United States and PEDMARQSI® in Europe and the U.K., as well as licensing developments with Norgine Pharmaceuticals Ltd. Updates on investigator-initiated and investigator-sponsored trials, including studies in Japan and at institutions such as City of Hope, provide insight into how PEDMARK® is being evaluated across different tumor types, age groups and geographies.
The Fennec news stream also covers financing transactions and balance sheet actions, such as underwritten public offerings of common shares, non-brokered offerings in Canada, and the use of proceeds to repurchase and redeem senior secured floating rate convertible notes issued to Petrichor Opportunities Fund I LP and Petrichor Opportunities Fund I Intermediate LP. These items help investors understand how the company funds commercialization and clinical collaborations while managing its capital structure.
Additional releases may highlight participation in healthcare conferences, changes in institutional shareholdings, and other corporate communications. By following this page, readers can access an organized view of Fennec’s official disclosures, from clinical data readouts and commercialization updates to securities offerings and debt redemptions, all in one place.
Southpoint Capital Advisors LP announced that on Dec 24, 2025 it disposed of beneficial ownership of 1,000,000 common shares of Fennec Pharmaceuticals (TSX: FENC), representing approximately 2.93% of outstanding common shares on a fully diluted basis. The Common Shares were sold at USD $7.50 per share. After the disposition, Southpoint reports it now controls or directs 2.7 million common shares, representing about 8% of outstanding shares on a fully diluted basis. Southpoint said the shares were disposed for investment purposes and that it may change its ownership or control through market transactions, private agreements, treasury issuances, or exercise of warrants.
Fennec Pharmaceuticals (NASDAQ:FENC) announced that City of Hope will initiate an investigator‑sponsored Phase I study (NCT07218913) to evaluate PEDMARK® (sodium thiosulfate) for prevention of cisplatin‑induced ototoxicity in adult men with stage II‑III metastatic testicular germ cell tumors on Dec 9, 2025. The study tests adding PEDMARK to standard cisplatin chemotherapy to reduce permanent hearing loss. PEDMARK is approved for pediatric localized non‑metastatic solid tumors and has a NCCN 2A recommendation for adolescent and young adult patients. Multiple other investigator‑initiated studies are under review or contracting, with additional details to be shared as programs progress.
Fennec Pharmaceuticals (NASDAQ: FENC) reported positive topline results from the investigator‑initiated Phase 2/3 STS-J01 study of PEDMARK® in Japan to reduce cisplatin‑induced hearing loss in pediatric and AYA patients.
The primary cohort (n=27, ages 3–18) met its endpoint: hearing loss rates were 24% (ASHA) and 16% (Brock) with PEDMARK®, versus historically reported cisplatin‑only rates of 56% (ASHA) and 63% (Brock). Pharmacokinetics showed no reduction in cisplatin exposure and tumor response rate was approximately 95%. PEDMARK® was well tolerated; no adverse events were attributed to the drug. Fennec plans to pursue registration in Japan and explore partnering or licensing opportunities.
Fennec Pharmaceuticals (NASDAQ: FENC) will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on December 3, 2025 at 1:00 p.m. ET. The session will be available via live webcast and an archived replay will be posted after the event.
Investors can access the live webcast via the provided webcast link or from the Events page in the Investors section of the company website (www.fennecpharma.com).
Fennec Pharmaceuticals (NASDAQ:FENC) announced it has repurchased and redeemed all outstanding convertible notes held by Petrichor Opportunities Fund I LP and Petrichor Opportunities Fund I Intermediate LP, leaving the company with no outstanding debt.
The repurchase used proceeds from the company’s underwritten public offering in the U.S. and concurrent private placement in Canada, which closed on November 17–18, 2025. The aggregate repurchase and redemption price was $21,729,455.30 (comprised of $19,476,655.48 principal, $305,134.27 accrued interest, and a $1,947,665.55 redemption fee). The Petrichor notes had carried interest at prime with a 3.5% floor plus a 4.5% margin and were set to mature on August 19, 2027.
Fennec Pharmaceuticals (NASDAQ:FENC) announced on November 18, 2025 the closing of a non‑brokered Canadian offering of common shares to certain institutional shareholders at US$7.50 per share, raising aggregate gross proceeds of US$5,025,000. The offering was made under the listed issuer financing exemption (Part 5A of NI 45‑106) to purchasers in Canada except Quebec, and the issued shares were registered under the Securities Act of 1933 via a prospectus supplement and accompanying prospectus. Because the offering used the listed issuer financing exemption, the issued common shares are not subject to a Canadian hold period. An offering document is available on SEDAR+ and the company website. The press release clarifies the offering was sold solely in Canada and is not an offer in jurisdictions where registration or qualification is required.
Fennec Pharmaceuticals (NASDAQ:FENC) closed an underwritten registered public offering on Nov 17, 2025 of 5,366,667 common shares at $7.50 per share, including full exercise of the underwriters' option. Gross proceeds before fees were approximately $40,250,000. The company intends to use net proceeds to repurchase and redeem certain indebtedness, with remaining funds for working capital and general corporate purposes. Piper Sandler and Craig-Hallum acted as joint book-running managers; H.C. Wainwright and Stephens served as additional managers. The offering was conducted under a registration statement declared effective by the SEC.
Fennec Pharmaceuticals (NASDAQ:FENC; TSX:FRX) announced a non-brokered private offering in Canada of common shares at US$7.50 per share to certain existing institutional shareholders for aggregate gross proceeds of up to US$5,025,000. The offering is expected to close on November 17, 2025, subject to subscription agreements, customary closing conditions and receipt of required approvals including the Toronto Stock Exchange.
The offering will be made under the listed issuer financing exemption (except Quebec) and the company expects to register any shares in the U.S. under the Securities Act via a prospectus supplement. There is no assurance the offering will complete or the amount raised if completed.
Fennec Pharmaceuticals (NASDAQ:FENC) priced an underwritten public offering of 4,666,667 common shares at $7.50 per share, with gross proceeds expected to be approximately $35,000,000 before discounts and expenses.
The underwriters have a 30‑day option to purchase up to an additional 700,000 shares. The offering is expected to close on November 17, 2025, and net proceeds are planned to repay and redeem indebtedness with any remainder for working capital and general corporate purposes.
Fennec Pharmaceuticals (NASDAQ:FENC) announced on November 13, 2025 a proposed underwritten registered public offering of common shares. The company said it will grant the underwriters a 30-day option to purchase up to an additional 15% of the shares sold.
Fennec intends to use net proceeds to repurchase and redeem certain indebtedness, with any remaining proceeds for working capital and general corporate purposes. Piper Sandler and Craig-Hallum are joint book-running managers. The offering will be made under a registration statement declared effective by the SEC and the shares will not be offered in Canada.
FAQ
What is the current stock price of Fennec Pharmaceuticals (FENC)?
What is the market cap of Fennec Pharmaceuticals (FENC)?
